3.4.23.38	(1S,2aR,3aR,3bS,4R,9aR,11aS)-2-(((1-(2-cyanophenyl)-1H-1,2,3-triazol-4-yl)methoxy)imino)-1-(furan-3-yl)-3b,6,6,9a,11a-pentamethyl-7-oxo-1,2,2a,3b,4,5,5a,6,7,9a,9b,10,11,11a-tetradecahydronaphtho(1,2':6,7)indeno(1,7a-b)oxiren-4-yl acetate	most active compound	239945	
3.4.23.38	(1S,2S,3S,4R)-3-(4-hexylphenylsulfonyl)-N-((2'-methoxybiphenyl-3-yl)methyl)-7-azabicyclo[2.2.1]heptan-2-amine	-	24787	
3.4.23.38	(1S,2S,3S,4R)-3-(4-hexylphenylsulfonyl)-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine	-	24788	
3.4.23.38	(1S,2S,3S,4R)-N-(3-bromobenzyl)-3-(4-hexylphenylsulfonyl)-7-azabicyclo[2.2.1]heptan-2-amine	-	24789	
3.4.23.38	(2R,3R)-4-(N-benzyl-N'-benzyloxycarbonyl-hydrazino)-2-(4-bromobenzyloxy)-3-hydroxy-N-((1S,2R)-2-hydroxyindan-1-yl)-butyramide	0.005 mM, 48% inhibition	52026	
3.4.23.38	(2R,3R)-4-(N-benzyl-N'-benzyloxycarbonyl-hydrazino)-2-(4-bromobenzyloxy)-3-hydroxy-N-(2-piperidin-1-yl-ethyl)-butyramide	0.005 mM, 35% inhibition	52027	
3.4.23.38	(2R,3R)-4-(N-benzyl-N'-benzyloxycarbonyl-hydrazino)-2-(4-bromobenzyloxy)-3-hydroxy-N-(2-piperidin-1-ylethyl)-butyramide	0.005 mM, 98% inhibition	22181	
3.4.23.38	(2R,3R)-4-(N-benzyl-N'-benzyloxycarbonyl-hydrazino)-2-(4-bromobenzyloxy)-3-hydroxy-N-(pyridin-3-yl-methyl)-butyramide	0.005 mM, 85% of maximal activity	33280	
3.4.23.38	(2R,3R)-4-(N-benzyloxycarbonylbenzylamino)-2-(4-bromobenzyloxy)-3-hydroxy-N-(2-piperidin-1-yl-ethyl)-butyramide	0.005 mM, 25% inhibition	52028	
3.4.23.38	(2R,3R)-4-(N-benzyloxycarbonylbenzylamino)-2-(4-bromobenzyloxy)-3-hydroxy-N-(pyridin-3-yl-methyl)-butyramide	0.005 mM, 36% inhibition	52029